Analyst Commentary On Deutsche Bank Aktiengesellschaft (DB), Progenics Pharmaceuticals, Inc. (PGNX)

Deutsche Bank Aktiengesellschaft (NYSE:DB) is struggling to gain traction with investors, as evidenced by its 6.45 million shares volume. The daily trading volume average remained 4 million shares over the course of 3 months. The stock had opened the regular trading at $16.8 and managed a -2.34% price change to reach $16.72 through the close.

Deutsche Bank Aktiengesellschaft (DB) Analyst Opinion

Deutsche Bank Aktiengesellschaft has a consensus hold rating from 30 Wall Street analysts, and the number of shares currently sold short amount to at least 2.51% of shares outstanding. The stock spiked 0.91% last month and is up 3.5 this year. Wall Street is only getting more bearish on the stock, with 4 of analysts who cover DB having a buy-equivalent rating. Analysts have placed a $14.32 price target on Deutsche Bank Aktiengesellschaft, suggesting a -14.35% decline from recent close. It’s currently trading about -14.17% below its 52-week high.

Deutsche Bank Aktiengesellschaft Earnings Surprise

Deutsche Bank Aktiengesellschaft (DB) failed to surprise the stock market in its last reported earnings when it earned $0.24 a piece versus the consensus-estimated $0.27. Its revenue totaled $7.16 billion down -2.53% from the previous quarter.

Deutsche Bank Aktiengesellschaft (NYSE:DB) Intraday View

This stock (DB) is ahead of its 52-week low with 40.64%. Its last month’s stock price volatility remained 1.16% which for the week stands at 1.07%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.3% and stays 0.83% away from its 50 days moving average. Over the last five days, shares have faced -0.89% losses and now is down -3.96% since hitting its 200-day moving average of $17.47. Deutsche Bank Aktiengesellschaft (DB) has made its way to a 12-month gain of 28.67%.

Turning to Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), its shares were trading at $5.86 a retreat of $-0.25, on the trading floor. The stock, after opening at $6.07, touched a high of $6.13 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. Progenics Pharmaceuticals, Inc. has 3 buy ratings, 0 holds and 0 sells even after the stock tumbled -50% from its high of $ 11.72 to a $417.58 million market value through last close.

Progenics Pharmaceuticals, Inc. (PGNX) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.4 to 1.4 during a month. Analysts set a 12-month price target of $13.5 a share. The target implies a 130.38% spike from where the shares are currently trading. Also, the current price highlights a discount of 155.97% to analysts’ high consensus price target.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Intraday Trading

The counter witnessed a trading volume of 0.78 million shares versus an average volume of 1.13 million shares during last trading session. Its last month’s stock price volatility remained 6.11% which for the week approaches 4.83%. The lowest price the stock reached in the last trading day was $5.82 and compares with the $4.60 52-week low. The stock recovered 27.39% since its low point and has performed -32.18% year-to-date.

Previous articleAnalyst Advice And Earnings Insight: Yamana Gold Inc. (AUY), Seattle Genetics, Inc. (SGEN)
Next articleAnalyst Commentary On Expedia, Inc. (EXPE), Vascular Biogenics Ltd. (VBLT)